RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that executives
from BioCryst are scheduled to present and provide a corporate summary
and update regarding the Company's clinical programs at the following
investor conferences:
-
Cowen & Co. 32nd Annual Healthcare Conference in
Boston, Massachusetts on Monday, March 5, 2012 at 4:50 p.m. Eastern
time
-
Roth Capital 24th Annual Growth Stock Conference in Dana
Point, California on Wednesday, March 14, 2012 at 1:30 p.m. Pacific
Time
Links to live audio webcasts and replays of both presentations may be
accessed on the BioCryst website at www.BioCryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel
small-molecule pharmaceuticals that block key enzymes involved in
infectious diseases, inflammatory diseases and cancer. BioCryst
currently has three novel late-stage compounds in development:
peramivir, a neuraminidase inhibitor for the treatment of influenza,
BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the
treatment of gout, and forodesine, an orally-available PNP inhibitor for
cancer, which is being developed by Mundipharma under a global
license agreement. Utilizing crystallography and structure-guided drug
design, BioCryst continues to discover additional compounds and to
progress others through preclinical and early development to address the
unmet medical needs of patients and physicians. For more information,
please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910
Source: BioCryst Pharmaceuticals
News Provided by Acquire Media